Asia branded business degrowth
Asia branded revenue declined 9% YoY in Q3 due to softer traction in certain markets and shipment delays.
medium · management_commentaryAjanta Pharma Limited — Q3 FY26
Ajanta Pharma delivered a strong Q3 FY26 with consolidated revenue of ₹1,375 crore (+20% YoY) and EBITDA of ₹382 crore (+19% YoY), driven by robust US generics (+52% YoY) and In...
bullish
high
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Competition in GLP-1 market in India
Analyst raised concern about intense competition in India GLP-1 market with 15-20+ players expected; management acknowledged but expects lower competition in emerging markets.
medium · analyst_questionForex volatility impact
9-month forex mark-to-market loss of ₹61 crore under other expenses, though no loss in Q3; currency movements remain a risk.
low · data_observationNew labor code cost impact
Additional provision of ₹7 crore made for new labor code liabilities; ongoing impact on staff costs.
low · management_commentary